Press Room

Event

AAPS 2021 PharmSci 360

Start
Sunday, October 17, 2021 - 00:00
End
Wednesday, October 20, 2021 - 00:00
Location: Philadelphia, USA
Booth Number: 1202
fully integrated solution provider for inhalation | Hovione

We are ready to safely return to AAPS PharmSci 360 in Philadelphia and we look forward to seeing you.

 

Schedule a meeting at the Hovione's booth (#1202) or online

Schedule a meeting button | Hovione
https://go.hovione.com/l/47122/2014-08-06/9grc

 

HOVIONE PRESENTATIONS AT AAPS

Join Hovione Scientists in their virtual oral presentations and poster abstracts and find out more about their latest research and innovation.

maria paisana Analytical Development Scientist | Hovione

 

Maria Paisana - Senior Analytical Scientist, Analytical Development Group

Presentation: Make it Flow: Can Ring Shear Tester Predict Flowability Through Hoppers?

Poster: Ring Shear Tester: The importance of Shear and Wall Friction Methodology for Arching Tendency Predictions

 





 

 
Luis Sobral Fellow Scientist R&D | Hovione

 

Luís Sobral - Fellow Scientist, R&D

Presentation: Modeling Chemical Reactions with Quantum Mechanics







 

Ricardo Gonçalves R&D Analytical Development | Hovione

Ricardo Gonçalves - Analytical Scientist, R&D Analytical Development

Presentation: Understanding Dry Powder Inhalers Formulations: Role of Surface Polarity of lactose mixtures





 

Beatriz Noriega-Fernandes Inhalation and Advanced Drug Delivery R&D | Hovione

 

Beatriz Noriega-Fernandes - Scientist, Inhalation and Advanced Drug Delivery Group, R&D

Poster: Spray-Dried Composite Formulation Containing DSPC for Lung Sustained Release





 

 
Luis Sousa R&D Analytical Development | Hovione

 

Luís Sousa - Senior Analytical Scientist, R&D Analytical Development

Poster: Evaluation of the Relaxation State of Amorphous Itraconazole Using Solution Calorimetry











 

From feasibility to commercial: Integrated Dry Powder Inhalation solutions to help bring inhaled medicines to patients

 

 

Hovione offers Customized high-performance APIs, Particle Engineering and Formulation along with a full range of highly specialized, innovative inhalation Devices. Our motto is Everything for Inhalation meaning great People, great Science and Technology combined with a strong Quality and Safety culture.





 

 

Let’s discuss your project together. 

 

Also in the Press Room

See All

Aim to accelerate drug development and production with new technologies. By: Charlie Sternberg Hovione, an international integrated pharmaceutical development and manufacturing organization, and Microinnova Engineering, a leader in continuous process intensification, have partnered to advance the development of multi-purpose, plug-and-play modular equipment for flow chemistry. The companies will work together to test Microinnova’s modular manufacturing equipment, which is designed to offer greater flexibility, easier scalability, enhanced efficiency, and sustainable practices in active ingredient production, in an industrial setting. Together, the companies aim to accelerate process development, facilitate a seamless transition from lab to large-scale manufacturing, and ultimately reduce the time to market for pharmaceutical customers. “This collaboration with Microinnova underscores Hovione’s commitment to innovation in pharmaceutical manufacturing, with flow chemistry playing an important role in our long-term drug substance strategy,” said Dr. Jean-Luc Herbeaux, CEO of Hovione. “This partnership will allow us to shape and validate emerging continuous manufacturing technologies, which can potentially accelerate drug development and production.” Dr. Dirk Kirschneck, Founder and Strategic Director at Microinnova, added, “This partnership reflects our shared vision to deliver modular manufacturing technologies that support pharmaceutical innovation and manufacturing excellence. We are proud to join forces with Hovione to showcase the capabilities of our next-generation modular equipment in a dynamic CDMO environment, demonstrating its versatility for multi-purpose manufacturing.”   Read the full article on ContractPharma.com  

Press Clipping
Contract Pharma, 24 September 2025

Hovione, Microinnova Partner to Test Modular Manufacturing Equipment

Sep 24, 2025

Hovione is a global contract development and manufacturing organization (CDMO) company founded in Portugal in 1959. With approximately 2,400 team members worldwide, the company provides comprehensive services for drug substances, drug intermediates, and drug products in countries around the world. Japan in particular plays a very important role in Hovione's global strategy, and in 2017 it established a Japanese subsidiary in Osaka. The company plans to actively invest in further strengthening its organization and recruiting personnel. With development labs strategically located in Lisbon, Portugal, and New Jersey, USA, Hovione consistently provides superior solutions tailored to complex pharmaceutical challenges. Hovione is recognized globally for its scientific excellence, technological innovation, and customer-centric and integrated approach. Leveraging cutting-edge capabilities in chemical synthesis, particle engineering, and formulation development, the company supports its partners throughout the entire pharmaceutical life cycle.   Read the full article in Japanese Read the article translated in English   Visit the Yakuji Nippo online      

Press Clipping
Yakuji Nippo Magazine, 2 July 2025

Solving Complex Pharmaceutical Challenges

Jul 10, 2025

The global inhalation contract development and manufacturing organization (CDMO) market is projected to grow from USD 9.13 billion in 2025 to USD 16.68 billion by 2035, reflecting a compound annual growth rate (CAGR) of 5.7% during the forecast period. This growth is driven by the increasing prevalence of respiratory diseases, advancements in inhalation drug delivery technologies, and the rising demand for outsourced manufacturing services in the pharmaceutical industry. The inhalation CDMO market has emerged as a pivotal segment in the pharmaceutical contract development and manufacturing industry. With a rising demand for inhaled therapies for conditions like asthma, COPD, and cystic fibrosis, companies are increasingly outsourcing drug development and production to specialized partners. Inhalation CDMO services cater to both large pharmaceutical corporations and small biotech firms, offering expertise in formulation, device compatibility, regulatory support, and scale-up manufacturing. This market is gaining traction due to the complexity of inhalation drug delivery, which often requires niche technical capabilities and specialized equipment. Outsourcing to an inhalation CDMO allows drug developers to reduce time-to-market while ensuring quality and compliance with global standards. (...) Top Companies Several players dominate the inhalation CDMO market through technological expertise, global reach, and service portfolio diversity: (...) Hovione – Offers particle engineering and inhalation development, with a focus on dry powder inhalers. (...) These companies are continually investing in facilities, talent, and technology to meet evolving customer needs in the inhalation CDMO market.   Read the full article on Pharmiweb.com        

Press Clipping
Pharmiweb.com, 25 June 2025

Inhalation CDMO Market Growth Analysis & Forecast 2025 to 2035

Jun 25, 2025

Also in Events

See All